Form 4: Elanco Director Lawrence Kurzius Increases Holdings Through Deferred Stock Units

Director Lawrence Kurzius increased his holdings in Elanco Animal Health Inc. through the acquisition of deferred stock units as part of the company's Directors' Deferral Plan.

Summary

• On March 29, 2024, Lawrence Kurzius, a director of Elanco Animal Health Inc., acquired 1,689.1892 deferred stock units.
• These units were obtained through the company's Directors' Deferral Plan, where director fees are deferred and converted into stock units.
• The price per share on the grant date was $16.28.
• Following this transaction, Mr. Kurzius directly owns 26,855.1443 deferred stock units.
• These units will be settled in stock after Mr. Kurzius' separation of service from the Company's Board of Directors.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The director increasing their stake in the company is generally a good sign, but it's part of a standard compensation plan.

Positives

• The acquisition of deferred stock units by a director signals confidence in the company's future performance.
• The Directors' Deferral Plan aligns the interests of directors with those of shareholders.

Future Outlook

The deferred stock units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

Industry Context

Directors receiving stock-based compensation is a common practice in the animal health industry to align management's interests with shareholder value. This filing reflects a standard compensation practice.

Comparison to Industry Standards

• Stock deferral plans are common among publicly traded companies, including those in the animal health sector.
• Companies like Zoetis and Merck Animal Health also utilize stock-based compensation for their directors and executives.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with shareholder value.

Key Dates